Skip to content

Released Nov 9, 2026, before the open

10-Q filed Nov 9, 2026, 40 days after period end · 0001764013-26-000122

Q2 2027 · 10-Q
Revenue—
Net Income-$97.25MN/M vs Q2 2026N/M vs Q1 2027
EPS Diluted-$0.47N/M vs Q2 2026N/M vs Q1 2027
Operating Cash Flowderived-$83,215,000N/M

What the release said

IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139).

IMVT-1402 600 mg met the primary ACR20 endpoint at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 of a potentially registrational trial in difficult-to-treat rheumatoid arthritis.21

Net loss for the three months ended September 30, 2026 was $97.2 million ($0.47 per common share), compared with $126.5 million ($0.73 per common share) for the same period in 2025.3

Immunovant's cash and cash equivalents totaled $722.3 million as of September 30, 2026.4

Immunovant said it expects it is unlikely to advance IMVT-1402 further in Sjögren's disease beyond the ongoing, fully enrolled Phase 2 trial.56

Research and development expenses were $85.0 million for the three months ended September 30, 2026, compared with $114.2 million for the three months ended September 30, 2025.7

ACR20 response at Week 28, IMVT-1402 600 mg
92.5% vs. 75.6% placebo, p=0.0139, Period 2 of the potentially registrational D2T RA trial1
Net loss, three months ended September 30, 2026
$97.2 million $0.47 per common share; compared to $126.5 million ($0.73 per common share) for the three months ended September 30, 20253
Cash and cash equivalents
$722.3 million As of September 30, 20264
Research and development expenses, three months ended September 30, 2026
$85.0 million Compared to $114.2 million for the three months ended September 30, 20257
General and administrative expenses, three months ended September 30, 2026
$19.1 million Compared to $17.5 million for the three months ended September 30, 20258
Net loss, six months ended September 30, 2026
$250.5 million $1.22 per common share; compared to $247.1 million ($1.43 per common share) for the six months ended September 30, 20259
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ2 2027Q2 2026Q2 2025Q2 2024
Net Income-$97.25M-$126.50M-$109.12M-$58.66M
EPS Diluted-$0.47-$0.73-$0.74-$0.45

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR